- Trials with a EudraCT protocol (303)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
303 result(s) found for: Base rate.
Displaying page 9 of 16.
EudraCT Number: 2007-003099-20 | Sponsor Protocol Number: CLL2O | Start Date*: 2007-11-06 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Ulm | ||||||||||||||||||
Full Title: A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymp... | ||||||||||||||||||
Medical condition: Patient with chronic lymphocytic leukemia (CLL) requiring therapy with a high risk factor such as 17p deletion or refractoriness to fludarabine . | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005537-35 | Sponsor Protocol Number: E5564-G000-301 | Start Date*: 2006-08-30 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis | |||||||||||||
Medical condition: Severe Sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) AT (Completed) CZ (Completed) ES (Completed) DE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004534-28 | Sponsor Protocol Number: Hyp1-18/2016 | Start Date*: 2018-08-09 | |||||||||||
Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel | |||||||||||||
Full Title: Combined Randomized, Double-Blind, Dose-Confirming Phase 3a Study in Parallel Design to Assess the Efficacy and Safety of Topical 4-Week Treatment With 1% GPB Cream vs Placebo and Open-Label Phase... | |||||||||||||
Medical condition: Severe primary axillary hyperhidrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) HU (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005059-35 | Sponsor Protocol Number: TMP-2204-2021-47 | Start Date*: 2022-01-25 | ||||||||||||||||
Sponsor Name:F4-Pharma GmbH i.G. | ||||||||||||||||||
Full Title: Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0) | ||||||||||||||||||
Medical condition: Acute Respiratory Distress Syndrome (ARDS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) PT (Prematurely Ended) IT (Prematurely Ended) NL (Completed) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001286-28 | Sponsor Protocol Number: CA209172 | Start Date*: 2014-09-24 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... | ||||||||||||||||||
Medical condition: Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) IT (Completed) DE (Completed) GB (Completed) ES (Completed) NL (Completed) AT (Completed) DK (Completed) PT (Completed) IE (Completed) SE (Completed) FI (Completed) HU (Completed) CZ (Completed) GR (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017951-87 | Sponsor Protocol Number: ING112574 | Start Date*: 2011-06-28 | |||||||||||
Sponsor Name:Viiv Healthcare | |||||||||||||
Full Title: A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen. | |||||||||||||
Medical condition: HIV-1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PT (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001354-28 | Sponsor Protocol Number: D4200C00068 | Start Date*: 2006-08-29 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer | ||
Medical condition: medullary thyroid cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004675-31 | Sponsor Protocol Number: AMCmedonc17-010 | Start Date*: 2019-11-13 |
Sponsor Name:Academic Medical Center | ||
Full Title: A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on firs... | ||
Medical condition: pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) ES (Ongoing) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003208-37 | Sponsor Protocol Number: AL0704rP | Start Date*: 2008-01-18 | ||||||||||||||||
Sponsor Name:Allergopharma Joachim Ganzer KG | ||||||||||||||||||
Full Title: A multicentre multinational randomised, placebo-controlled, double-blind pivotal trial for the evaluation of safety and efficacy of specific immunotherapy with a cocktail of recombinant major aller... | ||||||||||||||||||
Medical condition: ICD classification code: J45.0 and J 30.1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002582-35 | Sponsor Protocol Number: MCI-196-E16 | Start Date*: 2013-03-14 | |||||||||||
Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC) | |||||||||||||
Full Title: A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects with Chronic Kidney Disease Stages 3b to 5 and with Hyperphosphataemia not on ... | |||||||||||||
Medical condition: Hyperphosphataemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009598-90 | Sponsor Protocol Number: 91782 | Start Date*: 2010-08-20 | |||||||||||
Sponsor Name:Bayer Health Care AG (study performed by Bayer Schering Pharma AG) | |||||||||||||
Full Title: An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1... | |||||||||||||
Medical condition: Patients with histologically confirmed breast cancer referred to MRM prior to surgery after XRM. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002632-75 | Sponsor Protocol Number: CLI-050000-04 | Start Date*: 2020-07-08 |
Sponsor Name:CHIESI FARMACEUTICI S.p.A | ||
Full Title: Multicenter, open-label, randomised trial to assess the efficacy and tolerability of poractant alfa (porcine surfactant, Curosurf®) in hospitalized patients with SARS-COV-19 acute respiratory distr... | ||
Medical condition: patients with SARS-COV-19 acute respiratory distress syndrome (ARDS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-004422-42 | Sponsor Protocol Number: ESKETINSUI2002 | Start Date*: 2017-10-02 | ||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
Full Title: A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensiv... | ||||||||||||||||||||||||||||
Medical condition: Major Depressive Disorder with Imminent Risk of Suicide | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: HU (Completed) ES (Restarted) BE (Completed) PL (Completed) IT (Completed) BG (Completed) FR (Completed) Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003389-26 | Sponsor Protocol Number: RG14-093 | Start Date*: 2015-01-12 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer | |||||||||||||
Medical condition: Oropharyngeal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006430-10 | Sponsor Protocol Number: CTKI258A2202 | Start Date*: 2009-06-22 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer. | |||||||||||||
Medical condition: In female patients with FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000102-33 | Sponsor Protocol Number: 69HCL16_0079 | Start Date*: 2018-03-22 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in children: a multicenter European randomized controlled trial | |||||||||||||
Medical condition: toxic shock syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Not Authorised) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002045-23 | Sponsor Protocol Number: GS-US-180-0104 | Start Date*: 2008-07-18 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects. | |||||||||||||
Medical condition: Antiretroviral treatment–naive subjects chronically infected with HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000123-13 | Sponsor Protocol Number: ML28794 | Start Date*: 2013-08-28 |
Sponsor Name:NV ROCHE SA | ||
Full Title: A single arm multi-center study investigating the at home administration of trastuzumab subcutaneous vial for the treatment of patients with HER2-positive early breast cancer | ||
Medical condition: TO INVESTIGATE THE AT HOME ADMINISTRTATION OF TRASTUZUMAB SUBCUTANEOUS VIAL FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002905-31 | Sponsor Protocol Number: RO-2455-405-RD | Start Date*: 2011-12-01 | ||||||||||||||||
Sponsor Name:Nycomed GmbH | ||||||||||||||||||
Full Title: Effect of roflumilast 500 μg tablets once daily at acute COPD exacerbations treated with standard therapy of oral steroids and antibiotics. A randomised, double-blind, placebo-controlled, parallel-... | ||||||||||||||||||
Medical condition: Acute exacerbations of chronic obstructive pulmonary disease (COPD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002374-82 | Sponsor Protocol Number: TAK-620-3001 | Start Date*: 2022-11-21 | |||||||||||
Sponsor Name:Takeda | |||||||||||||
Full Title: A Phase 3, Open-Label, Single-Arm Study to Assess the Efficacy, Safety, and Pharmacokinetics of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Japanese Recipients of a Hematopoie... | |||||||||||||
Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
